The effect of zidovudine on chronic myelopathy associated with HTLV-1

Gout, Olivier; Gessain, Antoine; Iba-Zizen, Mt.; Kouzan, S; Bolgert, Françis; Th�, G.; Lyon-Caen, O

doi:10.1007/bf00315691

Cited by 41 publications

(18 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Initial observational studies suggested clinical benefit and reduction of HTLV-I proviral load with zidovudine85, 86 and lamivudine25, which had demonstrated some in vitro activity against the HTLV-I reverse transcriptase87, 88. A randomized, double-blind, placebo controlled study of six months combination therapy with these two nucleoside analogues was conducted in sixteen patients24.…”

Section: Therapymentioning

confidence: 99%

Treatment of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis: Toward Rational Targeted Therapy

Jacobson

2008

Neurologic Clinics

View full text Add to dashboard Cite

Section: Therapymentioning

confidence: 99%

Treatment of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis: Toward Rational Targeted Therapy

Jacobson

2008

Neurologic Clinics

View full text Add to dashboard Cite

“…Drugs used in informal therapeutic trials have included corticosteroids, anabolic steroids, zidovudine (AZT), and vitamin C, [49][50][51] but none gave lasting benefit. Recently, Taylor and colleagues 52 have obtained evidence that lamivudine (3TC) (150 mg twice daily) can reduce the provirus load of HTLV-1.…”

Section: Spastic Paraparesismentioning

confidence: 99%

HTLV-1 infections

Bangham¹

2000

Journal of Clinical Pathology

107

View full text Add to dashboard Cite

Human T lymphotropic virus type 1 (HTLV-1) causes disabling and fatal diseases, yet there is no vaccine, no satisfactory treatment, and no means of assessing the risk of disease or prognosis in infected people. Recent research on the molecular virology and immunology of HTLV-1 shows the importance of the host's immune response in reducing the risk of these diseases, and is beginning to explain why some HTLV-1 infected people develop serious illnesses whereas most remain healthy life long carriers of the virus. These findings might be applicable to other persistent virus infections such as human immunodeficiency virus, hepatitis B, and hepatitis C. (J Clin Pathol 2000;53:581-586)

show abstract

“…This class of medications has been highly effective in the treatment of HIV/AIDS, leading to the slowing of that virus and disease associated with it, but these drugs have not shown any definitive benefit for those with HTLV. Studies with small sample sizes were conducted using zidovudine and lamivudine, but no statistically significant benefit was seen (Gout et al, 1991; Scadden, Freedman, & Robertson, 2008; Sheremata, Benedict, Squilacote, Sazant, & DeFreitas, 1993).…”

Section: Pharmacological Interventionsmentioning

confidence: 99%